Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

57.1%

-29.4% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 3

2(28.6%)

Phase 4

1(14.3%)

7Total

Phase 2(4)

Phase 3(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03615664Phase 2Completed

The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD

Role: lead

NCT04716075Phase 2Completed

Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)

Role: lead

NCT03229382Phase 2Terminated

Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse

Role: lead

NCT02323659Phase 4Terminated

Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas

Role: lead

NCT01481272Phase 2Completed

Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients

Role: lead

NCT01652261Phase 3Withdrawn

Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11)

Role: collaborator

NCT00801281Phase 3Completed

First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.

Role: lead

All 7 trials loaded